Discovery shows benzofuran derivatives improve oral efficacy and safety profile in inflammatory bowel disease, indicating their potential as therapeutics.
= 0.16 μM) and superior in vivo efficacy accompanied by an improved safety profile. This work establishes benzofuran-2-carboxylic acid derivatives as promising IBD therapeutics, providing a pharmacological tool for phosphatase-targeted immunomodulation.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of Medicinal Chemistry